Evonik and Siemens Advance CO2-to-Specialty Chemicals


Evonik and Siemens have launched the second phase of their joint research project, Rheticus II, which aims to produce specialty chemicals from carbon dioxide (CO2) and water, using renewable electricity and bacteria.
The project follows Rheticus I, under which the companies worked for two years to develop the basis for artificial photosynthesis using a bioreactor and electrolyzers. In the process, the electrolyzers convert CO2 and water into carbon monoxide (CO) and hydrogen. Special microorganisms then convert the CO in the gases into chemicals.
Over the coming months, the partners will combine the two separate units into a test facility to be installed at Evonik’s site in Marl, Germany. In addition, they will build a unit to process the liquid from the bioreactor to obtain pure chemicals.
The facility, which will produce butanol and hexanol for research purposes, will start operating in early 2020. Evonik said these chemicals are used, for example, as starting products for specialty plastics and food supplements. It added, however, that other specialty chemicals are conceivable, depending on the bacterial strain and conditions.
“In the future, this platform could be installed anywhere CO2 is available – for example, at power plants or biogas plants,” said Thomas Haas, responsible for the Rheticus project at Evonik.
Rheticus II will run until 2021 and receive funding of about €3.5 million from Germany’s Federal Ministry of Education and Research (BMBF).
most read

Ratcliffe: Chemical Industry in Europe at a Tipping Point
Ineos CEO Ineos calls on European politicians to save the chemical industry.

VCI Welcomes US-EU Customs Deal
The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.

BASF Sells Majority Stake in Coatings Business
BASF sells a majority stake in its coatings business to the investor Carlyle.

Novo Nordisk to Cut 9,000 Jobs Globally in Major Restructuring
Novo Nordisk announced a global workforce reduction of approximately 9,000 positions to streamline operations and reinvest DKK 8 billion (€1 billion) in growth opportunities for diabetes and obesity treatments.

Dow to Shut Down Three Upstream European Assets
Building on the April 2025 announcement, Dow will take actions across its three operating segments to support European profitability, resulting in the closure of sites in Germany and the UK.














